NewcelX appoints diabetes expert to scientific advisory board

NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Dr. Julien Boisdron to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.

Dr. Boisdron currently serves as Chief Medical Officer for a Swiss-based multinational pharmaceutical company, where he oversees strategic development of diabetes technologies and clinical programs. He brings more than two decades of experience in global diabetes care leadership.

In his advisory role, Dr. Boisdron will provide strategic guidance for IsletRx, NewcelX's stem-cell-derived islet cell therapy program for insulin-dependent Type 1 Diabetes. He will advise on translational strategy as the company advances the program toward clinical trials.

"I am honored to join NewCelX's Scientific Advisory Board and to collaborate on advancing next-generation therapies for diabetes," Dr. Boisdron said. "NewCelX's integrated platform, combining cell-therapy and neuroscience innovation, offers a compelling foundation to move potentially transformative treatments closer to patients."

Prof. Michel Revel, Chief Scientific Officer of NewcelX, said Dr. Boisdron's experience in diabetes care and global medical leadership will enhance the company's strategic direction for the IsletRx program.

Executive Chairman and CEO Ronen Twito noted that Type 1 Diabetes represents a core focus and key priority in NewcelX's clinical development strategy. The company is headquartered in Zurich, Switzerland, with research and development operations in Ness Ziona, Israel.

The information is based on a company press release.

You May Also Be Interested In

• RenovoRx receives USPTO notice of allowance for RenovoCath patent
• Greenland Mines announces 1-for-50 reverse split, field updates
• FDA grants fast track status to Rein Therapeutics drug for lung fibrosis